血栓
下调和上调
信号转导
化学
转录因子
医学
组织因子途径抑制剂
体内
内科学
内分泌学
细胞生物学
组织因子
生物
生物化学
凝结
基因
生物技术
作者
Alexander Akhmedov,Giovanni G. Camici,Martin F. Reiner,Nicole R. Bonetti,Sarah Costantino,Erik W. Holy,Remo D. Spescha,Simona Stivala,Ariane Schaub Clerigué,Thimoteus Speer,Alexander Breitenstein,Jasmin Manz,Christine Lohmann,Francesco Paneni,Jürg H. Beer,Thomas F. Lüscher
摘要
The lectin-like oxLDL receptor-1 (LOX-1) promotes endothelial uptake of oxidized low-density lipoprotein (oxLDL) and plays an important role in atherosclerosis and acute coronary syndromes (ACS). However, its role in arterial thrombus formation remains unknown. We investigated whether LOX-1 plays a role in arterial thrombus formation in vivo at different levels of oxLDL using endothelial-specific LOX-1 transgenic mice (LOX-1TG) and a photochemical injury thrombosis model of the carotid artery.In mice fed a normal chow diet, time to arterial occlusion was unexpectedly prolonged in LOX-1TG as compared to WT. In line with this, tissue factor (TF) expression and activity in carotid arteries of LOX-1TG mice were reduced by half. This effect was mediated by activation of octamer transcription factor 1 (Oct-1) leading to upregulation of the mammalian deacetylase silent information regulator-two 1 (SIRT1) via binding to its promoter and subsequent inhibition of NF-κB signaling. In contrast, intravenous injection of oxLDL as well as high cholesterol diet for 6 weeks led to a switch from the Oct-1/SIRT1 signal transduction pathway to the ERK1/2 pathway and in turn to an enhanced thrombotic response with shortened occlusion time.Thus, LOX-1 differentially regulates thrombus formation in vivo depending on the degree of activation by oxLDL. At low oxLDL levels LOX-1 activates the protective Oct-1/SIRT1 pathway, while at higher levels of the lipoprotein switches to the thrombogenic ERK1/2 pathway. These findings may be important for arterial thrombus formation in ACS and suggest that SIRT1 may represent a novel therapeutic target in this context.
科研通智能强力驱动
Strongly Powered by AbleSci AI